Navigation Links
VIVUS to Present at the Deutsche Bank BioFEST Conference
Date:12/1/2011

s. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  p
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
2. VIVUS to Present at the BioCentury NewsMakers Conference
3. VIVUS to Participate in Three Investor Conferences in September
4. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
5. VIVUS Reports First Quarter 2011 Financial Results
6. VIVUS to Present at Four Upcoming Investor Conferences in May
7. VIVUS to Present at the 10th Annual Needham Healthcare Conference
8. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
9. VIVUS to Present at Four Upcoming Investor Conferences
10. VIVUS to Present at Two Upcoming Investor Conferences
11. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... The Europe Thermal Protective Clothing ... provide crucial revenue forecasts. It estimates the market ... a CAGR of 7.5%, from 2013 to 2018. ... Thermal Protective Clothing market report for a glimpse ... by various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... , Nov. 27, 2014 Research ... "Global Palmitic Acid Industry Report 2014" report ... The Global Palmitic Acid Industry Report ... current state of the global palmitic acid industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:11/27/2014)... Spartan Bioscience today announced that it ... Safety (MFDS) regulatory approval for its Spartan RX ... less than 60 minutes from a non-invasive cheek swab. ... for doctors to determine therapeutic strategies for drugs metabolized ... of the world’s most commonly prescribed drugs such as ...
(Date:11/27/2014)... 27, 2014 First articles ... Elsevier , a world-leading provider of ... pleased to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... the forefront of applied sciences such as micro and ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... N.J., April 16 Medarex, Inc.,(Nasdaq: MEDX ... trial that suggest a,potential association between higher doses ... disease control and prolonged,progression-free survival in patients with ... Phase 1/2 trial were presented at the,Annual Meeting ...
... BASINGSTOKE, England and PHILADELPHIA, April 16 /PRNewswire-FirstCall/,-- Shire ... SHPGY ), the,global specialty biopharmaceutical company, announces ... company proposal, it,will today post the Circular and ... to the ordinary shares in the new Shire ...
Cached Biology Technology:Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 2Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 3New Shire Holding Company Proposal 2New Shire Holding Company Proposal 3
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... CHAPEL HILL, NC In one of the ... adolescent delinquency, sociological research published in the August ... identifies three genetic predictorsof serious and violent delinquencythat ... influences, such as family, friends and school processes. ...
... PHILADELPHIA Although colorectal cancer screening tests are proven to ... and women 50 and older receive the recommended tests, according ... Cancer Epidemiology, Biomarkers and Prevention , a journal of the ... Disease Control and Prevention conducted a National Health Interview Survey ...
... Using an engineered common cold virus, UCLA researchers delivered ... them, using Positron Emission Tomography (PET), to locate the ... the first place prostate cancer goes before invading other ... lymph nodes are very difficult to find using conventional ...
Cached Biology News:Sociological research shows combined impact of genetics, social factors on delinquency 2Colorectal cancer screening rates still too low 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 3
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
...
...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Biology Products: